1376 related articles for article (PubMed ID: 27756421)
21. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
[TBL] [Abstract][Full Text] [Related]
22. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
Dubois B; Tolosa E; Katzenschlager R; Emre M; Lees AJ; Schumann G; Pourcher E; Gray J; Thomas G; Swartz J; Hsu T; Moline ML
Mov Disord; 2012 Sep; 27(10):1230-8. PubMed ID: 22915447
[TBL] [Abstract][Full Text] [Related]
23. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
Erkinjuntti T; Kurz A; Small GW; Bullock R; Lilienfeld S; Damaraju CV;
Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497
[TBL] [Abstract][Full Text] [Related]
24. Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
Rockwood K; Howlett SE; Hoffman D; Schindler R; Mitnitski A
Alzheimers Dement; 2017 Oct; 13(10):1098-1106. PubMed ID: 28341540
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
[TBL] [Abstract][Full Text] [Related]
26. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
[TBL] [Abstract][Full Text] [Related]
27. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.
Lenz RA; Pritchett YL; Berry SM; Llano DA; Han S; Berry DA; Sadowsky CH; Abi-Saab WM; Saltarelli MD
Alzheimer Dis Assoc Disord; 2015; 29(3):192-9. PubMed ID: 25973909
[TBL] [Abstract][Full Text] [Related]
28. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
[TBL] [Abstract][Full Text] [Related]
29. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
30. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
[TBL] [Abstract][Full Text] [Related]
32. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
Doody RS; Geldmacher DS; Gordon B; Perdomo CA; Pratt RD;
Arch Neurol; 2001 Mar; 58(3):427-33. PubMed ID: 11255446
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
34. Donepezil for mild and moderate Alzheimer's disease.
Birks JS; Melzer D; Beppu H
Cochrane Database Syst Rev; 2000; (4):CD001190. PubMed ID: 11034704
[TBL] [Abstract][Full Text] [Related]
35. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.
Mazza M; Capuano A; Bria P; Mazza S
Eur J Neurol; 2006 Sep; 13(9):981-5. PubMed ID: 16930364
[TBL] [Abstract][Full Text] [Related]
36. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey R
Cochrane Database Syst Rev; 2003; (3):CD001190. PubMed ID: 12917900
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease.
Marek GJ; Katz DA; Meier A; Greco N; Zhang W; Liu W; Lenz RA
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S364-73. PubMed ID: 24418055
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia.
Gault LM; Ritchie CW; Robieson WZ; Pritchett Y; Othman AA; Lenz RA
Alzheimers Dement (N Y); 2015 Jun; 1(1):81-90. PubMed ID: 29854928
[TBL] [Abstract][Full Text] [Related]
39. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
40. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
